Abstract 305P
Background
Transition of HER2 status after neoadjuvant chemotherapy (NAC) has frequently been reported previously; however, few study has focused on HER2-low breast cancer. Here, we evaluated the HER2 transition proportion among HER2-zero and HER2-low breast cancer cases post-NAC and the impact of clinical outcome after our initial report on pathologic complete response, long term outcomes and recurrence pattern in between two groups after neoadjuvant chemotherapy (S Kang, European Journal of Cancer, 2022).
Methods
We retrospectively reviewed HER2-zero and HER2-low breast cancer patients who underwent NAC and surgical resection during 2014–2018 at Asan Medical Center. We included 1288 patients who had paired pre- and post-therapeutic HER2 status results. HER2-zero was defined as immunohistochemistry (IHC)0, and HER2-low was defined as IHC1+ or IHC2+, with in situ hybridization-negativity.
Results
Of patients who were HER2-zero pre-NAC(n=650), 68% and 29% of patients were HER2-zero and HER2-low, respectively, post-NAC. Among patients who were HER2-low pre-NAC(n=638), 32% of patients showed HER2 changes, and 59% of patients had a constant HER2-low status post-NAC. Patients with constant HER2-low or transitions from HER2-low to zero had a higher proportion of hormone-receptor [HR] positivity (84% and 79%) than those with changes from HER2-zero to low (77%) or with constant HER2-zero (56%), respectively. Multivariable logistic regression analysis revealed that patients with HR positivity had a higher probability of gaining HER2-low expression than those with HR negativity (Odds ratio 2.48). No significant differences were observed in terms of overall survival and disease-free survival between patients with and without HER2-changes according to hormone receptor status, except in the post-therapeutic HER2-low HR-negative subset.
Conclusions
Temporal heterogeneity of HER2-low expression is observed in substantial portions of post-NAC breast cancer patients. Clinical outcomes show no significant associations, except in the post-therapeutic HER2-low, HR-negative subset. Prognostic implications of HER2 transition in HER2-low breast cancer require further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K.H. Jung: Non-Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Celgene, Eisai, Takeda, Novartis, Everest Medicine, Merck, Bixink. S. Kim: Non-Financial Interests, Institutional, Advisory Board: Lilly; Non-Financial Interests, Personal, Advisory Board: AstraZeneca, Daehwa Pharmaceutical, ISU Abxis, BeiGene, Daiichi Sankyo/AstraZeneca, OBI Pharma; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics, TC Corp, Genopeaks; Financial Interests, Personal, Other, Honoria: Daehwa Pharmaceutical, LegoChem Biosciences, Kalbe; Financial Interests, Institutional, Research Grant: Novartis, Dongkook Pharma, Genzyme. All other authors have declared no conflicts of interest.
Resources from the same session
325P - Impact of breast tumour location on axillary nodal involvement, chemotherapy use, and survival
Presenter: Yang Xu
Session: Poster session 02
326P - Sentinel lymph node mapping in breast cancer: Evaluating the dual-tracer method with indocyanine green and radioisotope
Presenter: Ava Kwong
Session: Poster session 02
328P - Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique
Presenter: Vanessa Petry
Session: Poster session 02
329P - Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy
Presenter: Jarle Karlsen
Session: Poster session 02
330P - Effect of radiotherapy in deep inspiration in patients with left breast cancer: Does the size of the target area affect the dose for the most crucial organs at risk?
Presenter: Zoltan Locsei
Session: Poster session 02
331P - miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ
Presenter: Tanja Marinko
Session: Poster session 02
332P - Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study
Presenter: Wei Li
Session: Poster session 02
333P - Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)
Presenter: Maeve Hennessy
Session: Poster session 02